Recommended Topic Related To:

Levulan Kerastick

"Aug. 5, 2013 -- Anyone who develops a rash, blister, or some other skin reaction while taking acetaminophen should stop using the drug and seek medical care immediately. The painkiller poses the risk for three rare but potentially fatal skin diso"...

Levulan Kerastick

Indications
Dosage
How Supplied

INDICATIONS

The LEVULAN KERASTICK (aminolevulinic acid) for Topical Solution plus blue light illumination using the BLU-U Blue Light Photodynamic Therapy Illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses (Grade 1 or 2, see table 2 for definition) of the face or scalp.

DOSAGE AND ADMINISTRATION

LEVULAN KERASTICK (aminolevulinic acid) for Topical Solution 20% is intended for direct application to individual lesions diagnosed as actinic keratoses and not to perilesional skin. This product is not intended for application by patients or unqualified medical personnel. Application should involve either scalp or face lesions, but not both simultaneously. Therecommended treatment frequency is: one application of the LEVULAN KERASTICK (aminolevulinic acid) Topical Solution and one dose of illumination per treatment site per 8-week treatment session. Each individual LEVULAN KERASTICK (aminolevulinic acid) should be used for only one patient. Photodynamic therapy for actinic keratoses with LEVULAN KERASTICK (aminolevulinic acid) for Topical Solution is a two stage process involving a) application of the product to the target lesions with LEVULAN KERASTICK (aminolevulinic acid) Topical Solution, followed 14 to 18 hours later by b) illumination with blue light using the BLU-U Blue Light Photodynamic Therapy Illuminator. The second visit, for illumination, must take place in the 14 18 hour window following application. Patients in clinical trials usually received application in the late afternoon, with illumination the following morning.

TABLE 6 - Schedule for LEVULAN and Blue Light Administration

LEVULAN KERASTICK
Topical Solution Application
Time Window for
Blue Light Illumination
6 am 8 pm to Midnight
7 am 9 pm to 1 am
8 am 10 pm to 2 am
9 am 11 pm to 3 am
10 am Midnight to 4 am
11 am 1 am to 5 am
12 pm 2 am to 6 am
1 pm 3 am to 7 am
2 pm 4 am to 8 am
3 pm 5 am to 9 am
4 pm 6 am to 10 am
5 pm 7 am to 11 am
6 pm 8 am to Noon
7 pm 9 am to 1 pm
8 pm 10 am to 2 pm
9 pm 11 am to 3 pm
10 pm Noon to 4 pm

Treated lesions that have not completely resolved after 8 weeks may be treated a second time with LEVULAN KERASTICK (aminolevulinic acid) for Topical Solution Photodynamic

Therapy. Patients did not receive follow-up past 12 weeks after the initial treatment, so the incidence of recurrence of treated lesions past 12 weeks and the role of further treatment is not known.

Step A - LEVULAN KERASTICK (aminolevulinic acid) for Topical Solution Application: Actinic keratoses targeted for treatment should be clean and dry prior to application of LEVULAN KERASTICK (aminolevulinic acid) for Topical Solution.

Preparation

The LEVULAN KERASTICK (aminolevulinic acid) Topical Solution should be prepared as follows:

1. Hold the LEVULAN KERASTICK (aminolevulinic acid) so that the applicator cap is pointing up.

Preparation of LEVULAN KERASTICK Topical Solution - Illustration 1

2. Crush the bottomampule containing the solution vehicle by applying finger pressure to Position A on the cardboard sleeve.

Preparation of LEVULAN KERASTICK Topical Solution - Illustration 2

3. Crush the top ampule containing the ALA HCl powder by applying finger pressure to Position B on the cardboard sleeve. NOTE: To ensure both ampules are crushed continue crushing the applicator downward, applying finger pressure to Position A.

Preparation of LEVULAN KERASTICK Topical Solution - Illustration 3

4. Holding the LEVULAN KERASTICK (aminolevulinic acid) between the thumb and forefinger, point the applicator cap away from the face, shake the LEVULAN KERASTICK (aminolevulinic acid) gently for at least 3 minutes to completely dissolve the drug powder in the solution vehicle. Do not press on the end cap while shaking.

Preparation of LEVULAN KERASTICK Topical Solution - Illustration 4

LEVULAN KERASTICK (aminolevulinic acid) Preparation: Following solution admixture, remove the cap from the LEVULAN KERASTICK (aminolevulinic acid) . The dry applicator tip should be dabbed on a gauze pad until uniformly wet with solution.

Application

Apply the solution directly to the target lesions by dabbing gently with the wet applicator tip. Enough solution should be applied to uniformly wet the lesion surface, including the edges without excess running or dripping. The effect of LEVULAN KERASTICK (aminolevulinic acid) Topical Solution on ocular tissues is unknown. LEVULAN KERASTICK Topical Solution should not be applied to the periorbital area or allowed to contact ocular or mucosal surfaces. Once the initial application has dried, apply again in the same manner. The LEVULAN KERASTICK (aminolevulinic acid) Topical Solution must be used immediately following preparation (dissolution) due to the instability of the activated product. If the solution application is not completed within 2 hours of activation, the applicator should be discarded and a new LEVULAN KERASTICK for Topical Solution used.

Photosensitization of the treated lesions will take place over the next 14-18 hours. The actinic keratoses should not be washed during this time. The patient should be advised to wear a wide brimmed hat or other protective apparel to shade the treated actinic keratosis lesions from sunlight or other bright light sources until BLU-U treatment. The patient should be advised to reduce light exposure if the sensations of stinging and/or burning are experienced.

If for any reason the patient cannot be given BLU-U treatment during the prescribed time after LEVULAN KERASTICK (aminolevulinic acid) Topical Solution application, he or she may nonetheless experience sensations of stinging and/or burning if the photosensitized actinic keratoses are exposed to sunlight or prolonged or intense light at that time. The patient should be advised to wear a wide-brimmed hat or other protective apparel to shade the treated actinic keratosis lesions from sunlight or other bright light sources until at least 40 hours after the application of LEVULAN KERASTICK Topical Solution. The patient should be advised to reduce light exposure if the sensations of stinging and/or burning are experienced.

Step B - Administration of BLU-U Treatment 14 to 18 hours after application of LEVULAN

KERASTICK Topical Solution: At the visit for light illumination, the actinic keratoses to be treated should be gently rinsed with water and patted dry. Photoactivation of actinic keratoses treated with LEVULAN KERASTICK (aminolevulinic acid) Topical Solution is accomplished with BLU-U illumination from the BLU-U Blue Light Photodynamic Therapy Illuminator. A 1000 second (16 minutes 40 seconds) exposure is required to provide a 10 J/cm² light dose. During light treatment, both patients and medical personnel should be provided with blue blocking protective eyewear, as specified In the BLU-U Operating Instructions, to minimize ocular exposure. Please refer to the BLU-U Operating Instructions for further information on conducting the light treatment. Patients should be advised that transient stinging and/or burning at the target lesion sites occurs during the period of light exposure.

If blue light treatment with the BLU-U Blue Light Photodynamic Therapy Illuminator is interrupted or stopped for any reason, it should not be restarted and the patient should be advised to protect the treated lesions from exposure to sunlight or prolonged or intense light for at least 40 hours after application of the LEVULAN KERASTICK (aminolevulinic acid) Topical Solution from the first visit.

For patients with facial lesions:

  1. The BLU-U Blue Light Photodynamic Therapy Illuminator is positioned so that the base is slightly above the patient's shoulder, parallel to the patient's face.
  2. The BLU-U is positioned around the patient's head so the entire surface area to be treated lies between 2“ and 4“ from the BLU-U surface:
    1. The patient's nose should be no closer than 2“ from the surface;
    2. The patient's forehead and cheeks should be no further than 4“ from the surface;
    3. The sides of the patient's face and the patient's ears should be no closer than 2“ from the BLU-U surface.

A Chin Rest, available from DUSA Pharmaceuticals, Inc., may be used to provide support for the patient's head during treatment.

For patients with scalp lesions:

  1. The knobs on either side of the BLU-U are loosened and the BLU-U is rotated to a horizontal position.
  2. The BLU-U is positioned around the patient's head so the entire surface area to be treated lies between 2" and 4" from the BLU-U surface:
    1. The patient's scalp should be no closer than 2" from the surface;
    2. The patient's scalp should be no further than 4" from the surface;
    3. The sides of the patient's face and the patient's ears should be no closer than 2" from the BLU-U surface.

A Chin Rest, available from DUSA Pharmaceuticals, Inc., may be used to provide support for the patient's head during treatment.

LEVULAN KERASTICK (aminolevulinic acid) for Topical Solution is not intended for use with any device other than the BLU-U Blue Light Photodynamic Therapy Illuminator. Use of LEVULAN KERASTICK (aminolevulinic acid) for Topical Solution without subsequent BLU-U illumination is not recommended.

HOW SUPPLIED

The LEVULAN KERASTICK (aminolevulinic acid) for Topical Solution, 20%, is a single-unit dosage form, supplied in packs of 6. Each LEVULAN KERASTICK (aminolevulinic acid) for Topical Solution applicator consists of a plastic tube containing two sealed glass ampules and an applicator tip. One ampule contains 1.5 mL of solution vehicle. The other ampule contains 354 mg of aminolevulinic acid HCl. The applicator is covered with a protective cardboard sleeve and cap.

Product Package NDC number
Individual LEVULAN KERASTICK for Topical Solution, 20% 67308-101-01
Carton of 6 LEVULAN KERASTICKS for Topical Solution, 20% 67308-101-06

Storage Conditions: Store between 20°- 25 °C (68°- 77°F); excursions permitted to 15°- 30 °C (59°- 86 °F) [See USP Controlled Room Temperature].The LEVULAN KERASTICK (aminolevulinic acid) for Topical Solution should be used immediately following preparation (dissolution). Solution application must be completed within 2 hours of preparation. An applicator that has been prepared must be discarded 2 hours after mixing (dissolving) and a new LEVULAN KERASTICK (aminolevulinic acid) for Topical Solution used, if needed.

Manufactured for: DUSA Pharmaceuticals, Inc. 25 Upton Drive Wilmington, MA 01887. FDA revision date: 7/11/2003

Last reviewed on RxList: 10/8/2008
This monograph has been modified to include the generic and brand name in many instances.

Indications
Dosage
How Supplied
A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.


From WebMD